|1.||Tscheiner, Michelle: 2 articles (05/2005 - 01/2005)|
|2.||Mazur, Adam W: 2 articles (05/2005 - 01/2005)|
|3.||Donnelly, Elizabeth: 2 articles (05/2005 - 01/2005)|
|4.||Wang, Feng: 2 articles (05/2005 - 01/2005)|
|5.||Isfort, Robert J: 2 articles (05/2005 - 01/2005)|
|6.||Hauger, Richard L: 1 article (09/2013)|
|7.||Hudson, Christine C: 1 article (09/2013)|
|8.||Hernandez-Aranda, Judith: 1 article (09/2013)|
|9.||Dautzenberg, Frank M: 1 article (09/2013)|
|10.||Olivares-Reyes, J Alberto: 1 article (09/2013)|
05/01/2005 - "Corticotropin releasing factor 2 receptor selective analogs of the amphibian peptide sauvagine, a member of the corticotropin releasing factor (CRF) peptide family, have therapeutic potential for the treatment of skeletal muscle atrophy. "
01/13/2005 - "Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy."
01/01/2004 - "In addition, we also observed that removal of the adrenals increased the effectiveness of the non-selective CRFR agonists sauvagine, presumably via the removal of the pro-atrophy influence of adrenal produced corticosteroids. "
06/13/1994 - "In rats kept at an ambient temperature of 22 degrees C, centrally and peripherally administered sauvagine induces a dose-dependent hypothermia. "
03/01/1990 - "Experiments with centrally or peripherally injected sauvagine produced dose-dependent hypothermia in rats kept at ambient temperatures of +4 degrees C and +22 degrees C, but no effect was seen on rats maintained at +34 degrees C. "
|4.||Hypotension (Low Blood Pressure)
|7.||Adrenal Cortex Hormones (Corticosteroids)